Cytokinetics extends GSK collaboration

Cytokinetics has added another year to its research collaboration pact with GlaxoSmithKline. That's the third extension for the biotech, which signed up with Glaxo back in 2001. Their partnership has delivered one early-stage cancer drug candidate now in early stage trials. Release

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.